P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance

Cancer

Volumn 77, Issue 9, 1996, Pages 1892-1898

  Lee, Jihjong J ^a   Hughes, Christine S ^a   Fine, Robert L ^b   Page, Rodney L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b The New York Presbyterian Hospital   (United States)

Author keywords

canine; lymphoma; multidrug resistance; P glycoprotein

Indexed keywords

GLYCOPROTEIN P;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; GENE EXPRESSION REGULATION; IMMUNOREACTIVITY; LYMPHOMA; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0029965253     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U     Document Type: Article

References (21)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
2. Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J Nat Cancer Inst 1992;84:711-6.
3. Chabner BA, Bates SE, Fojo AT, Spolyar M, Wilson WH. Drug resistance in adult lymphomas. Semin Hematol 1994;31:70-87.
4. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:1-78.
5. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, et al. Lymphomas in dogs. Cancer 1990;66: 480-90.
6. Turker MS, Duffin KZ, Smith AC, Martin GM, Martin AW, DiMartino DL, et al. Multidrug resistance phenotype associated with selection of aminopterin resistant dog kidney cell line. Pharmacogenetics 1991;11:149-60.
7. Lieberman DM, Reithmeier RAF, Ling V, Charuk JHM, Goldberg H, Skorecki KL. Identification of P-glycoprotein in renal brush border membranes. Biochem Biophys Res Commun 1989;162:244-52.
8. Moore AS, Leveille CR, Reimann KA, Shu H, Arias IM. The expression of P-Glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995; 13:475-9.
9. Rosenberg SA, Berard CW, Brown BW, Burke J, Dorfman RF, Glatstein E, et al. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
10. Gebhard DH, Carter PB. Identification of canine T-lymphocyte subsets with monoclonal antibodies. Vet Immunol Immunopathol 1992;33:187-99.
11. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992;52:3768-75.
12. Matus RE. Chemotherapy of lymphoma and leukemia. Kirk RE, editor. Current Veterinary Therapy X. Philadelphia: W.B. Saunders. 1989;482-9.
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. JASA 1958;53:457-81.
14. Prentice RL. Linear rank tests with right censored data. Biometrika 1978;65:167-179.
15. Teske E, Wisman P, Moore PF, van Heerde P. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Exp Hematol 1994;22:1179-87.
16. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989;49:1422-8.
17. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-Glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
18. Rodriguez C, Commes T, Robert J, Rossi JF. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's Lymphoma. Leuk Res 1993;17A:149-56.
19. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other pre-disposing factors. J Clin Oncol 1993;11:109-15.
20. Wilson WH, Bates SE, Fojo T, Bryant G, Zhan A, Regis J, et al. Controlled trial of dexverapamil, amodulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
21. Kang Y, Bryant G, Shives B, Stetler-Stevenson MA, Jaffe E, Wilson WH, et al., editors. Quantitative PCR analysis of mdr-1 in non-Hodgkin's Lymphoma [abstract]. Proceedings of the 84th meeting of the AACR; 1993;1280:214.